{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:25:34Z","timestamp":1760711134574,"version":"3.37.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202858","81472800"],"award-info":[{"award-number":["82202858","81472800"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022QH009","2019GSF108083"],"award-info":[{"award-number":["ZR2022QH009","2019GSF108083"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cell cycle checkpoint kinases play a pivotal role in protecting against replicative stress. In this study, valproic acid (VPA), a histone deacetylase inhibitor (HDACi), was found to promote breast cancer MCF-7 cells to traverse into G2\/M phase for catastrophic injury by promoting PPP2R2A (the B-regulatory subunit of Phosphatase PP2A) to facilitate the dephosphorylation of Chk1 at Ser317 and Ser345. By contrast, VPA protected normal 16HBE cells from HU toxicity through decreasing PPP2R2A expression and increasing Chk1 phosphorylation. The effect of VPA on PPP2R2A was at the post-transcription level through HDAC1\/2. The in vitro results were affirmed in vivo. Patients with lower PPP2R2A expression and higher pChk1 expression showed significantly worse survival. PPP2R2A D197 and N181 are essential for PPP2R2A-Chk1 signaling and VPA-mediated bidirectional effect on augmenting HU-induced tumor cell death and protecting normal cells.<\/jats:p>","DOI":"10.1038\/s41419-023-05649-8","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T13:03:20Z","timestamp":1676293400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["VPA mediates bidirectional regulation of cell cycle progression through the PPP2R2A-Chk1 signaling axis in response to HU"],"prefix":"10.1038","volume":"14","author":[{"given":"Benyu","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2837-0973","authenticated-orcid":false,"given":"David","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5785-1813","authenticated-orcid":false,"given":"Chenyang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1671-2646","authenticated-orcid":false,"given":"Zhihui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"5649_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Prim. 2019;5:66.","journal-title":"Nat Rev Dis Prim"},{"key":"5649_CR2","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147\u201359.","journal-title":"N Engl J Med"},{"key":"5649_CR3","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41556-018-0256-3","volume":"21","author":"I Keklikoglou","year":"2019","unstructured":"Keklikoglou I, Cianciaruso C, Guc E, Squadrito ML, Spring LM, Tazzyman S, et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol. 2019;21:190\u2013202.","journal-title":"Nat Cell Biol"},{"key":"5649_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","volume":"173","author":"C Kim","year":"2018","unstructured":"Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell 2018;173:879\u201393.e13.","journal-title":"Cell"},{"key":"5649_CR5","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.cmet.2018.04.018","volume":"27","author":"T Wang","year":"2018","unstructured":"Wang T, Fahrmann JF, Lee H, Li YJ, Tripathi SC, Yue C, et al. JAK\/STAT3-regulated fatty acid beta-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab. 2018;27:1357.","journal-title":"Cell Metab"},{"key":"5649_CR6","doi-asserted-by":"publisher","unstructured":"Jia B, Lim D, Zhang Y, Dong C, Feng Z. Global research trends in radiotherapy for breast cancer: a systematic bibliometric analysis. Jpn J Radiol. 2023. https:\/\/doi.org\/10.1007\/s11604-022-01383-x.","DOI":"10.1007\/s11604-022-01383-x"},{"key":"5649_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.molcel.2010.01.021","volume":"37","author":"E Petermann","year":"2010","unstructured":"Petermann E, Orta ML, Issaeva N, Schultz N, Helleday T. Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol Cell. 2010;37:492\u2013502.","journal-title":"Mol Cell"},{"key":"5649_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1586\/era.11.175","volume":"12","author":"K Madaan","year":"2012","unstructured":"Madaan K, Kaushik D, Verma T. Hydroxyurea: a key player in cancer chemotherapy. Expert Rev Anticancer Ther. 2012;12:19\u201329.","journal-title":"Expert Rev Anticancer Ther"},{"key":"5649_CR9","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/nar\/gkr748","volume":"40","author":"Z Feng","year":"2012","unstructured":"Feng Z, Zhang J. A dual role of BRCA1 in two distinct homologous recombination mediated repair in response to replication arrest. Nucleic Acids Res. 2012;40:726\u201338.","journal-title":"Nucleic Acids Res"},{"key":"5649_CR10","doi-asserted-by":"publisher","first-page":"681278","DOI":"10.3389\/fonc.2021.681278","volume":"11","author":"B Su","year":"2021","unstructured":"Su B, Lim D, Tian Z, Liu G, Ding C, Cai Z, et al. Valproic acid regulates HR and cell cycle through MUS81-pRPA2 pathway in response to hydroxyurea. Front Oncol. 2021;11:681278.","journal-title":"Front Oncol"},{"key":"5649_CR11","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1158\/1078-0432.CCR-09-1029","volume":"16","author":"Y Dai","year":"2010","unstructured":"Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res. 2010;16:376\u201383.","journal-title":"Clin Cancer Res"},{"key":"5649_CR12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/421486a","volume":"421","author":"J Bartek","year":"2003","unstructured":"Bartek J, Lukas J. DNA repair: damage alert. Nature. 2003;421:486\u20138.","journal-title":"Nature."},{"key":"5649_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","volume":"126","author":"Z Qiu","year":"2018","unstructured":"Qiu Z, Oleinick NL, Zhang J. ATR\/CHK1 inhibitors and cancer therapy. Radiother Oncol. 2018;126:450\u201364.","journal-title":"Radiother Oncol"},{"key":"5649_CR14","doi-asserted-by":"publisher","first-page":"503422","DOI":"10.1016\/j.mrgentox.2021.503422","volume":"873","author":"C Ding","year":"2022","unstructured":"Ding C, Su B, Li Q, Ding W, Liu G, Cai Z, et al. Histone deacetylase inhibitor 2-hexyl-4-pentynoic acid enhances hydroxyurea therapeutic effect in triple-negative breast cancer cells. Mutat Res Genet Toxicol Environ Mutagen. 2022;873:503422.","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"5649_CR15","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1158\/0008-5472.CAN-20-0057","volume":"80","author":"Z Qiu","year":"2020","unstructured":"Qiu Z, Fa P, Liu T, Prasad CB, Ma S, Hong Z, et al. A genome-wide pooled shRNA screen identifies PPP2R2A as a predictive biomarker for the response to ATR and CHK1 inhibitors. Cancer Res. 2020;80:3305\u201318.","journal-title":"Cancer Res"},{"key":"5649_CR16","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1017\/erm.2020.3","volume":"22","author":"HL Smith","year":"2020","unstructured":"Smith HL, Southgate H, Tweddle DA, Curtin NJ. DNA damage checkpoint kinases in cancer. Expert Rev Mol Med. 2020;22:e2.","journal-title":"Expert Rev Mol Med"},{"key":"5649_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","volume":"17","author":"T Otto","year":"2017","unstructured":"Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17:93\u2013115.","journal-title":"Nat Rev Cancer"},{"key":"5649_CR18","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3390\/ijms21061960","volume":"21","author":"L Ding","year":"2020","unstructured":"Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, et al. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci. 2020;21:1960.","journal-title":"Int J Mol Sci"},{"key":"5649_CR19","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.3390\/ijms20092353","volume":"20","author":"G Giannone","year":"2019","unstructured":"Giannone G, Tuninetti V, Ghisoni E, Genta S, Scotto G, Mittica G, et al. Role of cyclin-dependent kinase inhibitors in endometrial cancer. Int J Mol Sci. 2019;20:2353.","journal-title":"Int J Mol Sci"},{"key":"5649_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03096-0","volume":"9","author":"A Goder","year":"2018","unstructured":"Goder A, Emmerich C, Nikolova T, Kiweler N, Schreiber M, Kuhl T, et al. HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130. Nat Commun. 2018;9:764.","journal-title":"Nat Commun"},{"key":"5649_CR21","first-page":"1","volume":"1795","author":"PJ Eichhorn","year":"2009","unstructured":"Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta. 2009;1795:1\u201315.","journal-title":"Biochim Biophys Acta"},{"key":"5649_CR22","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1016\/j.cell.2021.04.022","volume":"184","author":"SJ Vervoort","year":"2021","unstructured":"Vervoort SJ, Welsh SA, Devlin JR, Barbieri E, Knight DA, Offley S, et al. The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. Cell. 2021;184:3143\u201362.e32.","journal-title":"Cell"},{"key":"5649_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.biocel.2017.10.008","volume":"96","author":"CM O\u2019Connor","year":"2018","unstructured":"O\u2019Connor CM, Perl A, Leonard D, Sangodkar J, Narla G. Therapeutic targeting of PP2A. Int J Biochem Cell Biol. 2018;96:182\u201393.","journal-title":"Int J Biochem Cell Biol"},{"key":"5649_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2016.12.018","volume":"65","author":"M Godfrey","year":"2017","unstructured":"Godfrey M, Touati SA, Kataria M, Jones A, Snijders AP, Uhlmann F. PP2A(Cdc55) phosphatase imposes ordered cell-cycle phosphorylation by opposing threonine phosphorylation. Mol Cell. 2017;65:393\u2013402.e3.","journal-title":"Mol Cell"},{"key":"5649_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nature13302","volume":"509","author":"MS Kim","year":"2014","unstructured":"Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Chaerkady R, et al. A draft map of the human proteome. Nature 2014;509:575\u201381.","journal-title":"Nature"},{"key":"5649_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/bs.acr.2019.03.009","volume":"144","author":"H Fowle","year":"2019","unstructured":"Fowle H, Zhao Z, Grana X. PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer. Adv Cancer Res. 2019;144:55\u201393.","journal-title":"Adv Cancer Res"},{"key":"5649_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-019-0180-9","volume":"8","author":"Z Zhao","year":"2019","unstructured":"Zhao Z, Kurimchak A, Nikonova AS, Feiser F, Wasserman JS, Fowle H, et al. PPP2R2A prostate cancer haploinsufficiency is associated with worse prognosis and a high vulnerability to B55alpha\/PP2A reconstitution that triggers centrosome destabilization. Oncogenesis 2019;8:72.","journal-title":"Oncogenesis"},{"key":"5649_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/nrm2851","volume":"11","author":"ME Moynahan","year":"2010","unstructured":"Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol. 2010;11:196\u2013207.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5649_CR29","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/ijms18071414","volume":"18","author":"T Eckschlager","year":"2017","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18:1414.","journal-title":"Int J Mol Sci"},{"key":"5649_CR30","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","volume":"19","author":"YH Kim","year":"2018","unstructured":"Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1192\u2013204.","journal-title":"Lancet Oncol"},{"key":"5649_CR31","first-page":"859","volume":"12","author":"P Smolewski","year":"2017","unstructured":"Smolewski P, Robak T. The discovery and development of romidepsin for the treatment of T-cell lymphoma. Expert Opin Drug Discov. 2017;12:859\u201373.","journal-title":"Expert Opin Drug Discov"},{"key":"5649_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.dnarep.2017.08.002","volume":"58","author":"Y Tian","year":"2017","unstructured":"Tian Y, Liu G, Wang H, Tian Z, Cai Z, Zhang F, et al. Valproic acid sensitizes breast cancer cells to hydroxyurea through inhibiting RPA2 hyperphosphorylation-mediated DNA repair pathway. DNA Repair. 2017;58:1\u201312.","journal-title":"DNA Repair"},{"key":"5649_CR33","doi-asserted-by":"publisher","first-page":"646256","DOI":"10.3389\/fonc.2021.646256","volume":"11","author":"G Liu","year":"2021","unstructured":"Liu G, Lim D, Cai Z, Ding W, Tian Z, Dong C, et al. The valproate mediates radio-bidirectional regulation through RFWD3-dependent ubiquitination on Rad51. Front Oncol. 2021;11:646256.","journal-title":"Front Oncol"},{"key":"5649_CR34","doi-asserted-by":"publisher","first-page":"e2301","DOI":"10.21769\/BioProtoc.2301","volume":"7","author":"A Luigi","year":"2017","unstructured":"Luigi A, Giordano A, Pentimalli F. DNA fiber assay upon treatment with ultraviolet radiations. Bio Protoc. 2017;7:e2301.","journal-title":"Bio Protoc"},{"key":"5649_CR35","doi-asserted-by":"publisher","first-page":"7554","DOI":"10.1093\/nar\/gkab584","volume":"49","author":"B Peng","year":"2021","unstructured":"Peng B, Shi R, Bian J, Li Y, Wang P, Wang H, et al. PARP1 and CHK1 coordinate PLK1 enzymatic activity during the DNA damage response to promote homologous recombination-mediated repair. Nucleic Acids Res. 2021;49:7554\u201370.","journal-title":"Nucleic Acids Res"},{"key":"5649_CR36","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1039\/C5TX00476D","volume":"5","author":"Y Luo","year":"2016","unstructured":"Luo Y, Wang H, Zhao X, Dong C, Zhang F, Guo G, et al. Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway. Toxicol Res. 2016;5:859\u201370.","journal-title":"Toxicol Res"},{"key":"5649_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.dnarep.2015.06.005","volume":"33","author":"C Dong","year":"2015","unstructured":"Dong C, Zhang F, Luo Y, Wang H, Zhao X, Guo G, et al. p53 suppresses hyper-recombination by modulating BRCA1 function. DNA Repair. 2015;33:60\u20139.","journal-title":"DNA Repair"},{"key":"5649_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tox.2018.03.003","volume":"400-401","author":"B Su","year":"2018","unstructured":"Su B, Guan Q, Wang M, Liu N, Wei X, Wang S, et al. Calpeptin is neuroprotective against acrylamide-induced neuropathy in rats. Toxicology. 2018;400-401:1\u20138.","journal-title":"Toxicology."},{"key":"5649_CR39","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.molcel.2016.12.007","volume":"65","author":"R Buisson","year":"2017","unstructured":"Buisson R, Niraj J, Rodrigue A, Ho CK, Kreuzer J, Foo TK, et al. Coupling of homologous recombination and the checkpoint by ATR. Mol Cell. 2017;65:336\u201346.","journal-title":"Mol Cell"},{"key":"5649_CR40","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1016\/j.molcel.2021.07.040","volume":"81","author":"F Meng","year":"2021","unstructured":"Meng F, Yu Z, Zhang D, Chen S, Guan H, Zhou R, et al. Induced phase separation of mutant NF2 imprisons the cGAS-STING machinery to abrogate antitumor immunity. Mol Cell. 2021;81:4147\u201364.e7.","journal-title":"Mol Cell"},{"key":"5649_CR41","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.21873\/anticanres.14319","volume":"40","author":"T Miyata","year":"2020","unstructured":"Miyata T, Takamura H, Kin R, Nishiki H, Hashimoto A, Fujii Y, et al. Spleen volume as a predictive biomarker for thrombocytopenia and liver dysfunction after oxaliplatin-based chemotherapy. Anticancer Res. 2020;40:3361\u201370.","journal-title":"Anticancer Res"},{"key":"5649_CR42","doi-asserted-by":"publisher","first-page":"e63181","DOI":"10.7554\/eLife.63181","volume":"10","author":"H Fowle","year":"2021","unstructured":"Fowle H, Zhao Z, Xu Q, Wasserman JS, Wang X, Adeyemi M, et al. PP2A\/B55alpha substrate recruitment as defined by the retinoblastoma-related protein p107. Elife 2021;10:e63181.","journal-title":"Elife"},{"key":"5649_CR43","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.molcel.2008.08.006","volume":"31","author":"Y Xu","year":"2008","unstructured":"Xu Y, Chen Y, Zhang P, Jeffrey PD, Shi Y. Structure of a protein phosphatase 2A holoenzyme: insights into B55-mediated Tau dephosphorylation. Mol Cell. 2008;31:873\u201385.","journal-title":"Mol Cell"},{"key":"5649_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03327-4","volume":"9","author":"L Zhang","year":"2018","unstructured":"Zhang L, Zhou H, Li X, Vartuli RL, Rowse M, Xing Y, et al. Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression. Nat Commun. 2018;9:1047.","journal-title":"Nat Commun"},{"key":"5649_CR45","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1172\/JCI127692","volume":"129","author":"S Yun","year":"2019","unstructured":"Yun S, Hu R, Schwaemmle ME, Scherer AN, Zhuang Z, Koleske AJ, et al. Integrin alpha5beta1 regulates PP2A complex assembly through PDE4D in atherosclerosis. J Clin Investig. 2019;129:4863\u201374.","journal-title":"J Clin Investig"},{"key":"5649_CR46","doi-asserted-by":"publisher","first-page":"e58081","DOI":"10.7554\/eLife.58081","volume":"9","author":"L Pan","year":"2020","unstructured":"Pan L, Lemieux ME, Thomas T, Rogers JM, Lipper CH, Lee W, et al. IER5, a DNA damage response gene, is required for Notch-mediated induction of squamous cell differentiation. Elife. 2020;9:e58081.","journal-title":"Elife"},{"key":"5649_CR47","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ebiom.2019.09.054","volume":"49","author":"P Chen","year":"2019","unstructured":"Chen P, Wang B, Mo Q, Wu P, Fang Y, Tian Y, et al. The LIV-1-GRPEL1 axis adjusts cell fate during anti-mitotic agent-damaged mitosis. EBioMedicine 2019;49:26\u201339.","journal-title":"EBioMedicine"},{"key":"5649_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04671-1","volume":"9","author":"K Schott","year":"2018","unstructured":"Schott K, Fuchs NV, Derua R, Mahboubi B, Schnellbacher E, Seifried J, et al. Dephosphorylation of the HIV-1 restriction factor SAMHD1 is mediated by PP2A-B55alpha holoenzymes during mitotic exit. Nat Commun. 2018;9:2227.","journal-title":"Nat Commun"},{"key":"5649_CR49","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/febs.13573","volume":"283","author":"J Sangodkar","year":"2016","unstructured":"Sangodkar J, Farrington CC, McClinch K, Galsky MD, Kastrinsky DB, Narla G. All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase. FEBS J. 2016;283:1004\u201324.","journal-title":"FEBS J"},{"key":"5649_CR50","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1158\/0008-5472.CAN-12-1667","volume":"72","author":"P Kalev","year":"2012","unstructured":"Kalev P, Simicek M, Vazquez I, Munck S, Chen L, Soin T, et al. Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition. Cancer Res. 2012;72:6414\u201324.","journal-title":"Cancer Res"},{"key":"5649_CR51","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cancergen.2011.05.002","volume":"204","author":"Y Cheng","year":"2011","unstructured":"Cheng Y, Liu W, Kim ST, Sun J, Lu L, Sun J, et al. Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study. Cancer Genet. 2011;204:375\u201381.","journal-title":"Cancer Genet"},{"key":"5649_CR52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10549-017-4403-5","volume":"166","author":"LF Watt","year":"2017","unstructured":"Watt LF, Panicker N, Mannan A, Copeland B, Kahl RGS, Dun MD, et al. Functional importance of PP2A regulatory subunit loss in breast cancer. Breast Cancer Res Treat. 2017;166:117\u201331.","journal-title":"Breast Cancer Res Treat"},{"key":"5649_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-363","volume":"14","author":"A Youn","year":"2013","unstructured":"Youn A, Simon R. Using passenger mutations to estimate the timing of driver mutations and identify mutator alterations. BMC Bioinform. 2013;14:363.","journal-title":"BMC Bioinform"},{"key":"5649_CR54","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/jhg.2017.91","volume":"62","author":"MM Zhu","year":"2017","unstructured":"Zhu MM, Li HL, Shi LH, Chen XP, Luo J, Zhang ZL. The pharmacogenomics of valproic acid. J Hum Genet. 2017;62:1009\u201314.","journal-title":"J Hum Genet"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05649-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05649-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05649-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T02:03:45Z","timestamp":1676340225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05649-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["5649"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-05649-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"type":"electronic","value":"2041-4889"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"assertion":[{"value":"2 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experimental animal procedures were approved by the Shandong University Human and Animal Ethics Research Committee (81472800, approved March 2014). Human tissue biological samples were approved by the ethics committee of Shanghai Outdo Biotech Company (YB M-05-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"114"}}